[go: up one dir, main page]

WO2011036883A1 - Agent antigrippal - Google Patents

Agent antigrippal Download PDF

Info

Publication number
WO2011036883A1
WO2011036883A1 PCT/JP2010/005762 JP2010005762W WO2011036883A1 WO 2011036883 A1 WO2011036883 A1 WO 2011036883A1 JP 2010005762 W JP2010005762 W JP 2010005762W WO 2011036883 A1 WO2011036883 A1 WO 2011036883A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
extract
inhibitor
karin
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2010/005762
Other languages
English (en)
Japanese (ja)
Inventor
清水　一史
玲子 黒田
貴仁 ▲高▼瀬
紗奈恵 菊池
桜井　孝治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lotte Co Ltd
Original Assignee
Lotte Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotte Co Ltd filed Critical Lotte Co Ltd
Priority to KR1020127010366A priority Critical patent/KR20120087928A/ko
Priority to CN2010800432467A priority patent/CN102573866A/zh
Priority to JP2011532910A priority patent/JPWO2011036883A1/ja
Publication of WO2011036883A1 publication Critical patent/WO2011036883A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to an anti-influenza virus agent, an influenza virus adsorption inhibitor, a virus mRNA synthesis inhibitor in influenza virus-infected cells, and a virus vRNA in influenza virus-infected cells, which contains a plant-derived extract having an influenza virus infection-suppressing action as an active ingredient.
  • the present invention relates to a synthesis inhibitor, a viral cRNA synthesis inhibitor in influenza virus-infected cells, a hemolysis inhibitor in a viral membrane fusion activity test, and an influenza virus envelope disruptor.
  • the influenza virus that causes the influenza epidemic is an RNA virus having an envelope membrane with a diameter of about 1 / 10,000 mm. Although it is classified into three types, A, B, and C, due to the difference in antigenicity, it is A type and B type that show a trendy spread. Two types of glycoproteins, hemagglutinin (HA) and neuraminidase (NA), protrude in the form of spikes on the surface of these virus particles, and gene RNA segmented into 8 segments exists inside. HA and NA on the surface of the virus frequently mutate within the same subtype, and new antigenic variants appear every year.
  • HA hemagglutinin
  • NA neuraminidase
  • Influenza virus released by cough droplets enters from the human nose and mouth, adsorbs to the mucosal epithelial cells of the upper respiratory tract by the spike-like glycoprotein HA on the surface of the virus, and begins to proliferate after entering the cells.
  • Recent research has revealed the mechanism of viral infection.
  • the virus binds to a receptor consisting of a sugar chain on the surface layer of human target cells, is taken into the endosome, enters the cell by fusion of the viral membrane and endosomal membrane, undergoes shelling and translocation, and the expression of the viral gene Replication occurs, and finally progeny virus particles are formed and propagated by budding from the host cell membrane.
  • influenza virus causes symptoms such as sudden fever, headache, joint pain, general malaise in a few days, followed by respiratory symptoms such as cough, sore throat, runny nose and stuffy nose. Unlike the so-called cold, it is highly infectious and causes an explosive epidemic in a short period of time.
  • the structure of the HA protein of influenza virus repeats mutations every year, and the fact that antibodies made by past infections are not very useful is also a factor that spreads infection.
  • antiviral drugs such as amantadine, rimantadine, and zanamivir have been developed, but side effects such as hypersensitivity, neuropsychiatric symptoms, digestive system symptoms, and autonomic nervous system symptoms have been reported. Caution must be taken.
  • influenza viruses are thought to be difficult to suppress by vaccination because influenza viruses infect and proliferate in the airway mucosal epithelium and the epidemic type of the year cannot be accurately predicted. Frequent gargling, avoiding throat dryness, and adequate nutrition and rest are currently considered the most effective preventive measures. Development of an anti-influenza virus agent that is highly effective in suppressing infection and has no safety problems and can be used on a daily basis is desired.
  • Non-patent Documents 1 and 2 polyphenol components of tea and black tea have been reported as anti-influenza materials derived from natural products (Non-patent Documents 1 and 2), and it has become clear that gargle of black tea suppresses actual viral infections through tests using humans. (Non-Patent Document 3). In addition, it has been reported that ougon-derived flavonoid components exhibit an influenza infection suppression effect due to viral sialidase inhibitory activity (Non-patent Document 4).
  • Patent Document 1 Kameda Futoshi Koshiketsu
  • Patent Document 2 Kuroburi Currant Extract
  • Patent Document 3 Potato Anthocyanin Pigment
  • Patent Document 4 Guava Leaf Extract
  • an anti-influenza agent containing an extract of the flower bud or petal as an active ingredient is disclosed (Patent Document 6), an extract of Karin (Patent Document 8), and a column fraction of Karin.
  • the anti-influenza virus effect of is reported.
  • influenza virus adsorption inhibitory effect of the column fraction of Karin shown in the patent of the present invention, the viral mRNA synthesis inhibitory effect in influenza virus-infected cells, the virus vRNA synthesis inhibitory effect in influenza virus-infected cells, and the virus cRNA in influenza virus-infected cells
  • the synthesis inhibitory effect the hemolysis inhibitory effect in the virus membrane fusion activity test, and the envelope destruction effect of influenza virus, which have been revealed for the first time by the present invention.
  • An object of the present invention is to use a highly safe plant extract that can be used with peace of mind on a daily basis, an influenza virus adsorption inhibitor, a virus mRNA synthesis inhibitor in influenza virus-infected cells, and a virus vRNA synthesis inhibitor in influenza virus-infected cells. It is intended to provide an agent, a virus replication inhibitor in influenza virus-infected cells, a hemolysis inhibitor in a virus membrane fusion activity test, and an influenza virus envelope disruptor.
  • the present inventors focused on highly safe kalin without side effects, and used RT-PCR analysis of mRNA, vRNA and cRNA in MDCK cells added with influenza virus, and chicken erythrocytes. The effect of the extract of karin on hemolysis and observation of virus particles with an electron microscope was found, and the product of the present invention was completed.
  • the present invention relates to an influenza virus adsorption inhibitor characterized by comprising an extract of karin (Chaenomeles sinensis, Pseudocydonia sinensis), a viral mRNA synthesis inhibitor in influenza virus-infected cells, and a virus in influenza virus-infected cells.
  • karin Choenomeles sinensis, Pseudocydonia sinensis
  • a viral mRNA synthesis inhibitor in influenza virus-infected cells and a virus in influenza virus-infected cells.
  • They are a vRNA synthesis inhibitor, a viral cRNA synthesis inhibitor in influenza virus-infected cells, a hemolysis inhibitor in a viral membrane fusion activity test, and an influenza virus envelope disruptor.
  • this invention is the food-drinks which have an anti-influenza virus effect
  • the present invention comprises a highly safe extract of karin as an active ingredient, an influenza virus adsorption inhibitor strong against influenza virus, a virus mRNA synthesis inhibitor in influenza virus-infected cells, a virus vRNA synthesis inhibitor in influenza virus-infected cells,
  • the present invention provides a virus replication inhibitor in influenza virus-infected cells, a hemolysis inhibitor in a virus membrane fusion activity test, and an envelope disruptor for influenza virus.
  • the extract of Karin which is an active ingredient of the present invention, has high safety, it can be adsorbed, impregnated and added to a mask, an air conditioner filter, clothing, wet tissue, a spray solution, etc. Can be widely used in daily life.
  • the product of the present invention is effective in preventing influenza virus infection and treating diseases caused by influenza virus.
  • the destruction activity to the viral envelope membrane of a karin extract is shown.
  • the adsorption inhibitory activity, vRNA synthesis inhibitory activity, mRNA synthesis inhibitory activity, and cRNA synthesis inhibitory activity of the karin extract are shown.
  • the hemolysis inhibitory activity of a karin extract is shown.
  • ⁇ It is desirable to use the fruits of karin as the raw material for the product of the present invention.
  • the method for obtaining the extract of the present invention from the pulverized plant is not particularly limited, but water, methanol, ethanol, n-propanol, and lower alcohols such as n-butanol, ether, ethyl acetate, acetone, glycerin, propylene glycol.
  • One or two or more mixed solvents of organic solvents such as these are added, and extraction is performed by a conventional extraction method.
  • the extraction condition is not particularly limited, but it is preferably about 1 to 5 hours at 50 to 90 ° C.
  • the extract can be filtered and the extraction solvent can be distilled off, followed by concentration or lyophilization under reduced pressure. Further, those obtained by fractionating and purifying these extracts by organic solvent fractionation, column chromatography or the like can also be used.
  • the form of use of the product of the present invention is not particularly limited, and powders, tablets, troches can be obtained by adding a solvent, a dispersant, a pharmaceutical carrier, an emulsifier, a diluent, a stabilizer, etc. to the plant extract exemplified as an active ingredient.
  • a solvent e.g., ethanol
  • emulsifier e.g., a sulfate
  • a diluent e.g., diluent
  • a diluent emulsifier
  • a diluent emulsifier
  • a diluent emulsifier
  • a diluent e.g., diluent
  • a stabilizer e.g., a stabilizer, etc.
  • the plant extract exemplified as an active ingredient.
  • an infection control product that can contribute to influenza prevention can be provided.
  • the amount of adsorbed and added plant extract in these applications varies depending on the form of the infection control product, and cannot be specified in general, but is added so that the proportion is 0.001 to 5% by weight. Is preferred.
  • the present invention is highly safe, for example, it is blended into confectionery such as chewing gum, candy, tablet confectionery, gummy jelly, chocolate and biscuits, ice cream, sorbet and other frozen confectionery, beverages, soups, jams and other food and drink, Can be used.
  • confectionery such as chewing gum, candy, tablet confectionery, gummy jelly, chocolate and biscuits, ice cream, sorbet and other frozen confectionery, beverages, soups, jams and other food and drink, Can be used.
  • the amount to be added varies depending on the form of use and the taste of the extract, but it is added in an amount of 0.001 to 5% by weight, preferably about 0.01 to 1% by weight based on the food or drink. Is preferred.
  • a reflux condenser is attached to a flask to which 300 g of dried Karin fruit and 3000 ml of 50% ethanol are added, and extraction is performed while refluxing for 1 hour. The obtained extract was filtered, the solvent was removed, and freeze-dried to obtain 69 g of extract.
  • the Karin 50% ethanol extract was applied to a Diaion HP20 (Mitsubishi Kasei) column. Elution was carried out in the order of water, 20% ethanol, 40% ethanol, and 60% ethanol. The component (CSD3) eluted with this ethanol concentration 40% aqueous solution was collected. The yield of this fraction was about 8.6 g as dry weight.
  • the phenol content of this product by the vanillin-hydrochloric acid method was 54% [based on ( ⁇ )-epicatechin], and it was confirmed that it mainly contained phenolic substances.
  • Viral adsorption inhibitory effect, vRNA synthesis inhibitory effect, mRNA synthesis inhibitory effect, and cRNA synthesis inhibitory effect by CSD3 were extracted from viral RNA and analyzed by RT-PCR.
  • a sample stock solution was prepared by dissolving CSD3 in 50% ethanol to 50 mg / ml.
  • Sample stock solutions are appropriately diluted with Tris-Glucose-Saline (TGS) (from 10 2 to 10 6- fold dilution), and 50 ⁇ l of these sample dilutions and virus solution (4 ⁇ 10 4 to 4 ⁇ 10 6 PFU (place forming unit) ) / Ml) 50 ⁇ l was mixed and allowed to react at room temperature for 10 minutes.
  • TGS Tris-Glucose-Saline
  • 0.1 ml of this was inoculated into a single-layer culture (6-well plate) of Madin-Darby canine kidney (MDCK) cells to which 0.4 ml of TGS was added, and the virus was adsorbed at room temperature for 30 minutes. After removing 0.5 ml of the culture solution and culturing at 37 ° C. for 0, 1, 2, 3, 4, 6, 8, 12 hours, the viral genomic RNA in the infected cells was dissolved in guanidine thiocyanate 25% It was recovered by ethanol precipitation. Details of the cDNA synthesis method and the PCR amplification method from RNA in each test method are shown below.
  • RNA a reverse transcriptase reaction was carried out using Super Script III (Invitrogen) reverse transcriptase and T7 cRNA (1-12) primer according to the attached instructions to synthesize vRNA cDNA.
  • PCR amplification was performed with a set of oligonucleotide primers specific to the virus (Udorn) NP gene. PCR was performed for 45 cycles (5 seconds, 95 ° C., 34 seconds, 64 ° C.) using SYBR Premix taq polymerase II (Invitrogen).
  • the number of vRNA copies per hole obtained is shown in FIG.
  • the adsorption copy number of CSD3 untreated virus at 0 hour was 6.7 ⁇ 10 8 / hole, but it was 2.2 ⁇ 10 8 / hole by 1 ⁇ g / ml CSD3 treatment, and adsorption was suppressed to about 1/3.
  • the amount of vRNA synthesized by the CSD3 untreated virus was 2.2 ⁇ 10 10 / well (after 12 hours of culture), whereas that of CSD3 treated at 1 ⁇ g / ml was 3.2 ⁇ 10 8 / well, and the amount of vRNA synthesized was about Reduced to 1/70.
  • RNA synthesis inhibition test In the virus primary / secondary transcription inhibition test by CSD3, reverse transcription was performed using reverse transcriptase and T7T (18) VN primer to synthesize mRNA cDNA. PCR was amplified with a set of oligonucleotide primers specific to the NP gene using the synthesized cDNA as a template. PCR was performed for 45 cycles (5 seconds, 95 ° C., 34 seconds, 64 ° C.) using SYBR Premix taq polymerase II (Invitrogen).
  • the number of mRNA copies per hole obtained is shown in FIG.
  • the copy number of mRNA of CSD3 untreated virus was 2.6 ⁇ 10 10 / well (after 12 hours of culture), whereas that of CSD3 treatment at 1 ⁇ g / ml was 4.3 ⁇ 10 7 / well, and the amount of mRNA synthesis was about Reduced to 1/600.
  • CRNA synthesis inhibition test In the viral replication stage suppression test using CSD3, reverse transcription was performed using reverse transcriptase and T7 vRNA (1-13) primer to synthesize cRNA cDNA. PCR was amplified with a set of oligonucleotide primers specific to the NP gene using the synthesized cDNA as a template. PCR was performed for 45 cycles (5 seconds, 95 ° C., 34 seconds, 64 ° C.) using SYBR Premix taq polymerase II (Invitrogen). The number of copies of cRNA obtained for each well is shown in FIG.
  • CSD3 untreated virus cRNA copy number was 9.7 ⁇ 10 6 / well (after 8 hours of culture), whereas 1 ⁇ g / ml CSD3 treatment was 2.5 ⁇ 10 4 / well, and the amount of cRNA synthesis was about Reduced to 1/400.
  • CSD3 was added to the virus (16000HA) and kept at room temperature for 1 hour. Observation of the virus particles with an electron microscope was performed by a negative staining method with 2% uranium acetate.
  • FIG. 1 is an electron microscopic image showing the disrupting activity of a karin extract (CSD3) on the virus envelope membrane, (a) shows the case of adding the karin extract, and (b) shows no addition of the karin extract. Show the case.
  • Prescription ethanol of spray liquid 25.0% by weight Citric acid 1.5% by weight Trisodium citrate 1.0 wt% CSD3 0.5 wt% Water remaining 100.0% by weight
  • Prescription sugar for tablet candy 76.1% by weight Glucose 19.0% by weight Sucrose fatty acid ester 0.2% by weight Fragrance 0.2 wt% CSD3 0.5 wt% Water remaining 100.0% by weight

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un inhibiteur de l'adsorption d'un virus grippal, un inhibiteur de la synthèse de l'ARNm viral dans les cellules infectées par le virus de la grippe, un inhibiteur de la synthèse de l'ARNv viral dans les cellules infectées par le virus de la grippe, un inhibiteur de la synthèse de l'ARNc viral dans les cellules infectées par le virus de la grippe, un agent antihémolytique pour une utilisation dans un test d'activité de fusion de la membrane virale et un agent pour rompre l'enveloppe d'un virus grippal, chacun utilisant un extrait de plante qui est hautement sécuritaire pour une utilisation sur une base quotidienne. L'invention concerne spécifiquement un agent antigrippal caractérisé en ce qu'il contient, en tant que principe actif, un extrait produit par extraction du coing avec de l'éthanol aqueux à 50 %, fractionnement de l'extrait résultant sur une colonne et purification du produit fractionné.
PCT/JP2010/005762 2009-09-24 2010-09-24 Agent antigrippal Ceased WO2011036883A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020127010366A KR20120087928A (ko) 2009-09-24 2010-09-24 항인플루엔자 바이러스제
CN2010800432467A CN102573866A (zh) 2009-09-24 2010-09-24 抗流感病毒剂
JP2011532910A JPWO2011036883A1 (ja) 2009-09-24 2010-09-24 抗インフルエンザウイルス剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009218643 2009-09-24
JP2009-218643 2009-09-24
JP2009278462 2009-12-08
JP2009-278462 2009-12-08

Publications (1)

Publication Number Publication Date
WO2011036883A1 true WO2011036883A1 (fr) 2011-03-31

Family

ID=43795649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/005762 Ceased WO2011036883A1 (fr) 2009-09-24 2010-09-24 Agent antigrippal

Country Status (5)

Country Link
JP (1) JPWO2011036883A1 (fr)
KR (1) KR20120087928A (fr)
CN (1) CN102573866A (fr)
TW (1) TW201125571A (fr)
WO (1) WO2011036883A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501798A (zh) * 2011-04-26 2014-01-08 罗蒂株式会社 抗新型流感病毒剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005343836A (ja) * 2004-06-04 2005-12-15 Lotte Co Ltd 抗インフルエンザウイルス剤及びこれを含有する感染抑制用品及び飲食物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100544750C (zh) * 2006-10-13 2009-09-30 解会元 药酒组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005343836A (ja) * 2004-06-04 2005-12-15 Lotte Co Ltd 抗インフルエンザウイルス剤及びこれを含有する感染抑制用品及び飲食物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. ETHNOPHARMACOL., vol. 118, 2008, pages 108 - 112 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501798A (zh) * 2011-04-26 2014-01-08 罗蒂株式会社 抗新型流感病毒剂

Also Published As

Publication number Publication date
CN102573866A (zh) 2012-07-11
TW201125571A (en) 2011-08-01
KR20120087928A (ko) 2012-08-07
JPWO2011036883A1 (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
JP4216013B2 (ja) 抗インフルエンザウイルス剤
KR101139376B1 (ko) 항인플루엔자 바이러스제 및 이를 함유하는 감염 억제용품 및 음식물
CA2721040C (fr) Extraits de procyanidine issus de la cannelle, des litchis et des arachides utiles dans le traitement d'infections retrovirales
KR20120118707A (ko) 신종인플루엔자, 조류인플루엔자, 일반 및 독감감기, ｓａｒｓ 바이러스 억제 효능을 갖는 오배자 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 약학 조성물
KR101782532B1 (ko) 백지 추출물 또는 이로부터 분리된 퓨라노쿠마린을 함유하는 조류 인플루엔자, 돼지 인플루엔자 또는 코로나 바이러스의 예방 또는 치료용 조성물
JP5653034B2 (ja) 抗ウイルス剤
KR102755978B1 (ko) 고사리 추출물 또는 이의 분획물을 포함하는 항바이러스용 조성물
WO2011036883A1 (fr) Agent antigrippal
JP2009269861A (ja) カシス果実由来のウィルス感染予防・治療剤
KR20210002378A (ko) 송화분 추출물을 유효성분으로 포함하는 간 보호용 조성물
US8603548B2 (en) Anti-avian influenza virus agent, and product containing anti-avian influenza virus agent
JP5303482B2 (ja) 抗インフルエンザウイルス剤及びこれを吸着、含浸、添加させてなるインフルエンザ感染抑制用品
JP5343016B2 (ja) 抗インフルエンザウイルス剤及びこれを吸着、含浸、添加させてなるインフルエンザ感染抑制用品
JP2012229178A (ja) 抗新型インフルエンザウイルス剤
KR102676865B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
TWI389700B (zh) 解決ｒｎａ病毒感染之新穎標準化組成物、製造方法及用途
KR102578871B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
HK1171944A (en) Anti-influenza virus agent
JP4847712B2 (ja) アカシア属樹皮由来物を含有する抗酸化組成物
HK1190922A (en) Pandemic influenza antiviral agent
JP2007223970A (ja) トリインフルエンザウイルス感染阻害剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080043246.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10818560

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011532910

Country of ref document: JP

Ref document number: 12012500575

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1201001291

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127010366

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10818560

Country of ref document: EP

Kind code of ref document: A1